MARK W. BENNETT, District Judge.
I. INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .675A. Factual Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . .675B. Procedural Background . . . . . . . . . . . . . . . . . . . . . . . . . . .678II. LEGAL ANALYSIS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .681A. Subject Matter Jurisdiction . . . . . . . . . . . . . . . . . . . . . . . .6811. Justiciability requirements . . . . . . . . . . . . . . . . . . . . . .6812. Nature of the defendants' challenge . . . . . . . . . . . . . . . . . .6823. Standing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .684a. Arguments of the parties . . . . . . . . . . . . . . . . . . . . . .684b. Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .686i. Standing of the direct purchaser plaintiffs . . . . . . . . .687ii. Standing of the principal and agent . . . . . . . . . . . . .690iii. The producer plaintiff . . . . . . . . . . . . . . . . . . . .690c. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6924. Ripeness . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .692a. Arguments of the parties . . . . . . . . . . . . . . . . . . . . . .692b. Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .693i. Fitness . . . . . . . . . . . . . . . . . . . . . . . . . . .693ii. Hardship . . . . . . . . . . . . . . . . . . . . . . . . . . .695c. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6965. Foreclosure by Ewing . . . . . . . . . . . . . . . . . . . . . . . . . .697a. Arguments of the parties . . . . . . . . . . . . . . . . . . . . . .697b. Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6986. Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .699B. Failure To Exhaust Administrative Remedies . . . . . . . . . . . . . . . . .6991. Arguments of the parties . . . . . . . . . . . . . . . . . . . . . . . .6992. Analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .700a. The administrative exhaustion requirement . . . . . . . . . . . . .700b. The necessity of exhaustion of the present claims . . . . . . . . .701c. The prudence of exhaustion of questions ante . . . . . . . . . . . .702III. CONCLUSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .703
Got [raw] milk? This lawsuit presents the interesting question of the validity of Food and Drug Administration (FDA) regulations requiring "milk" in final package form for beverage use to be pasteurized or ultrapasteurized and prohibiting the delivery
Because this matter is before the court on a motion to dismiss, the factual background is drawn primarily from the plaintiffs' Amended Complaint (docket no. 8). This statement of facts is supplemented, where appropriate, on a challenge to the court's subject matter jurisdiction, by facts drawn from affidavits in support of the plaintiffs' resistance to the defendants' motion to dismiss.
The court will describe six of the individual plaintiffs—Laurie Donnelly, Jennifer Allen, Dr. Joseph Heckman, Dane Miller, Cynthia Lee Rose, and Eric Wagoner, to the extent that his claims rely on the same conduct—as the "direct purchaser plaintiffs." All of the direct purchaser plaintiffs, with the exception of plaintiff Miller, allege that they reside in states where it is illegal to sell raw (unpasteurized) milk, even though it is legal to consume raw milk in those states.
Plaintiff Miller's allegations are somewhat different. Plaintiff Miller alleges that he is a citizen of Pennsylvania, where it is legal to sell raw milk, at least under certain conditions, but that he has relatives in Virginia, where it is not legal to sell raw milk. He alleges that, on more than one occasion, he drove from Virginia back to his home state of Pennsylvania, where he legally purchased and obtained raw milk in final package form from a licensed dairy
The allegations of two of the individual plaintiffs, Eric Wagoner and Anne Cooper, whom the court will describe as the "principal and agent plaintiffs," are different. In addition to his "direct purchaser" allegations, plaintiff Wagoner alleges that he is the owner of an internet-based "virtual farmers' market" based in Georgia that others may join by paying an annual membership fee. He alleges that it is illegal to sell raw dairy products in Georgia, but it is legal to sell them in South Carolina. He alleges that members of his virtual farmers' market residing in Georgia, including plaintiff Anne Cooper and himself, order raw milk in final package form for personal consumption from three dairies located in South Carolina who list their dairy products with the virtual farmers' market. Wagoner alleges that he drives to South Carolina to pick up the raw dairy products, returns with them to Georgia, and distributes them to the members of the virtual farmers' market who ordered them. Wagoner and Cooper allege that Wagoner was Cooper's agent to pick up the raw milk that she had ordered in South Carolina and to deliver it to her in Georgia. Wagoner alleges that the members pay the farmers for the products listed on the virtual farmers' market.
Wagoner alleges that, on October 15, 2009, he was driving from South Carolina to Georgia with about 110 gallons of raw milk in final package form ordered by members of his virtual farmers' market, but upon reaching Georgia, his truck was searched and seized and the raw milk in it was embargoed, without a warrant, by officials from Georgia. He alleges that, on October 19, 2009, he was ordered to and did destroy the 110 gallons of raw milk, including milk "owned" by himself and Cooper, by order of Georgia officials and the FDA, again without a warrant or other legal process.
Plaintiff Michael Buck, whom the court will describe as the "producer plaintiff," alleges that he owns and operates a dairy farm in South Carolina that is licensed by the State of South Carolina. He also alleges that he has held a retail raw milk license from the State of South Carolina since 2006. He alleges that it is legal to sell raw milk in South Carolina as long as the seller is either a licensed dairy farm or a licensed retail store. Buck alleges that approximately 25% of his milk is sold in
Plaintiff Farm-to-Consumer Legal Defense Fund (the "Fund" or "FTCLDF") alleges that it is a non-profit organization organized under the laws of the State of Ohio, with its principal place of business in Falls Church, Virginia. The Fund alleges that it consists of over 1,900 members from 49 different states. The Fund alleges that it is dedicated to protecting and promoting sustainable, environmentally sound farming practices and direct farm-to-consumer transactions, which the Fund believes further the common good and general welfare of all Americans. The Fund alleges that it defends and protects the right of farmers to directly provide, and for consumers to directly obtain, unprocessed and processed farm foods. Toward this end, the Fund alleges that it provides advocacy, education, and legal services for farmers and consumers against any local, state, and federal government interference with the legal transfer of products produced and processed on the farm. Plaintiffs Dr. Joseph Heckman, Eric Wagoner, and Michael Buck allege that they are members of the Fund.
All of the plaintiffs allege that they have chosen to support the preservation and protection of America's agricultural heritage and traditional farming techniques; the provision and delivery of foods produced thereby directly to the consumer; the maintenance and protection of heirloom varieties of plants and animals constituting a valuable genetic resource which may help to protect America's food supply in the event of a disease outbreak; and the contribution to the national security founded in a diverse and sustainable agricultural system in the event of a terrorist attack or natural disaster that interrupts the distant transportation of centrally-produced food across the country.
All of the plaintiffs also allege that they are, have been, and will be damaged and have suffered, are suffering, and will suffer an injury in fact by the prohibitions contained in regulations promulgated by the FDA, 21 C.F.R. §§ 1240.61 and 131.110, pursuant to the Food, Drug, and Cosmetics Act (FDCA) and the Public Health Service Act (PHSA). Section 1240.61 provides, in pertinent part, as follows:
21 C.F.R. § 1240.61(a). Section 131.110 provides, in pertinent part, as follows:
All of the plaintiffs allege that these regulations deprive them of the following fundamental and inalienable rights: (a) the right to travel across state lines with raw dairy products legally obtained and possessed; (b) the right to provide for the care and well being of themselves and their families, including their children; and (c) the right to produce, obtain, and consume the foods of choice for themselves and their families, including their children. The plaintiffs allege that they are also suffering injury from the promulgation and enforcement of regulations that are beyond the defendants' authority, arbitrary, and capricious.
The plaintiffs filed a Complaint (docket no. 2) initiating this action for declaratory and injunctive relief on February 20, 2010, and an Amended Complaint (docket no. 8) on March 18, 2010. In the Amended Complaint, the plaintiffs named as defendants Kathleen Sebelius, in her official capacity as Secretary of the United States Department of Health and Human Services (HHS), the HHS itself, Margaret Hamburg, in her official capacity as Commissioner of the United States Food and Drug Administration (FDA), and the FDA itself.
First,
Finally,
In addition to declaratory relief, the plaintiffs seek injunctive relief. Specifically, they pray that the court will enjoin any further enforcement—civil, criminal, administrative, or otherwise—of 21 C.F.R. § 1240.61 and 21 C.F.R. § 131.110 against the plaintiffs or anyone else who wishes to distribute or take across state lines raw
On April 26, 2010, the defendants filed a pre-answer Motion To Dismiss (docket no. 10), seeking dismissal of the Amended Complaint for lack of subject matter jurisdiction and failure to state claims upon which relief can be granted, pursuant to Rules 12(b)(1) and 12(b)(6) of the Federal Rules of Civil Procedure. On June 15, 2010, the plaintiffs filed a Resistance To Defendants' Motion To Dismiss (docket no. 17), with four affidavits attached. On April 21, 2010, the defendants filed a Reply (docket no. 19) in further support of their Motion To Dismiss.
The court heard oral arguments on the defendants' Motion To Dismiss on July 22, 2010. At the oral arguments, the plaintiffs were represented by David G. Cox in Columbus, Ohio, and Wallace L. Taylor in Cedar Rapids, Iowa, and the defendants were represented by Roger Gural and Jennifer Zachary, Trial Attorneys, Office of Consumer Litigation, Department of Justice, Civil Division, in Washington, D.C., Martha Fagg, Assistant United States Attorney, in Sioux City, Iowa, and Larry Kudje, Assistant United States Attorney, in Cedar Rapids, Iowa.
On July 24, 2010, two days after the oral arguments, the plaintiffs filed a Motion To Admit Newly Discovered Evidence (docket no. 24). The evidence in question consists of e-mails exchanged between a reporter for the Iowa Public Radio Network and a press officer for the FDA and e-mails thereafter exchanged between counsel for the parties. The defendants filed a Resistance To Plaintiffs' Motion To Admit Newly [Discovered] Evidence (docket no. 25) on July 30, 2010, and the plaintiffs filed a Reply (docket no. 26) in further support of their motion that same day.
Both the defendants' Motion To Dismiss and the plaintiffs' Motion To Admit Newly Discovered Evidence are now fully submitted.
In the portion of their Motion To Dismiss seeking dismissal pursuant to Rule 12(b)(1), the defendants assert that this court lacks subject matter jurisdiction over this action, because the plaintiffs do not have standing, their claims are not ripe for review, and their claims for declaratory and injunctive relief barring the government from applying the FDA's regulations to the plaintiffs are foreclosed by Ewing v. Mytinger & Casselberry, Inc., 339 U.S. 594, 70 S.Ct. 870, 94 L.Ed. 1088 (1950). The plaintiffs resist dismissal on these grounds.
As the Eighth Circuit Court of Appeals recently explained,
Gray v. City of Valley Park, Mo., 567 F.3d 976, 982-83 (8th Cir.2009).
The Eighth Circuit Court of Appeals has also explained that "`[c]ourts employ a number of doctrines to determine justiciability [for subject matter jurisdiction purposes] such as standing, ripeness, and mootness.'" Gray, 567 F.3d at 983 (quoting Schanou, 62 F.3d at 1042). The defendants' challenges to the court's subject matter jurisdiction here rest on two of these justiciability doctrines, standing and ripeness. "[I]f a plaintiff lacks standing, the district court has no subject matter jurisdiction." Id. at 981 (internal quotation marks and citations omitted). Similarly, "[t]he issue of ripeness, which has both Article III and prudential components, is one of subject matter jurisdiction." Dakota, Minnesota & Eastern Railroad Corp. v. South Dakota, 362 F.3d 512, 520 (8th Cir.2004). "A Rule 12(b)(1) motion challenges whether the district court has subject matter jurisdiction to hear the matter." Johnson v. United States, 534 F.3d 958, 964 (8th Cir.2008). The court will consider the defendants' challenges to subject matter jurisdiction under the standing and ripeness doctrines in turn.
Before considering the defendants' standing and ripeness challenges, however, the court must determine what, if anything, beyond the Amended Complaint it should consider to resolve those challenges. The specific question is whether the court should consider either the affidavits offered by the plaintiffs in support of their resistance to the defendants' Motion To Dismiss or the evidence identified in the plaintiffs' Motion To Admit Newly Discovered Evidence.
It is not altogether clear whether the defendants are mounting a facial or factual attack on subject matter jurisdiction. On the one hand, the defendants appear to challenge plaintiff Wagoner's allegations about the involvement of the FDA in the destruction of the raw milk that he transported from South Carolina to Georgia for members of his virtual farmers' market, as well as all of the plaintiffs' allegations that enforcement action by the FDA against them or similarly situated persons has occurred or is likely to occur. On the other hand, the defendants submitted no affidavits or other evidence to attempt to contradict the plaintiffs' jurisdictional allegations, and made no request for an evidentiary hearing. What is clear is that the defendants want the court to take their factual assertions in their brief as true, with no hearing and no evidentiary support, but not take the plaintiffs' factual allegations in their Amended Complaint as true nor consider the plaintiffs' affidavits and other evidence offered in support of their contentions that this court has subject matter jurisdiction.
The court finds that the ambiguous nature of the defendants' challenge to subject matter jurisdiction warrants considering, in the first instance, for whatever value it may have, the evidence offered by the plaintiffs in support of their resistance to the defendants' challenge to subject matter jurisdiction, including both the affidavits with their original resistance and the evidence submitted with their Motion To Admit Newly Discovered Evidence. Cf. Johnson, 534 F.3d at 964 (where the defendant makes a factual challenge to subject matter jurisdiction, the court has wide
The court's willingness to consider the plaintiffs' evidence, including their "newly discovered evidence," does not mean that the court is convinced that there is good cause for the plaintiffs' failure to supplement their response to the defendants' Motion To Dismiss with their purportedly "newly discovered evidence" prior to the oral arguments on the Motion To Dismiss or to offer their purportedly "newly discovered evidence" at the oral arguments. The plaintiffs admit that they came into possession of the "new" evidence before the oral arguments. Thus, their assertion that there was no way that they could have presented this evidence to the court except via a motion to admit new evidence after the oral arguments rings hallow. Instead, their conduct in reserving some evidence until after the court took the matter under advisement looks like gamesmanship. However, the court does not find that the defendants will be prejudiced by the court's consideration of the belatedly offered evidence, because it has little, if any, probative value on any question presented here, where the plaintiffs have made no showing that the FDA employee, identified by the defendants as a "press officer," involved in the e-mail exchanges with the public radio reporter had any policy-making authority or any authority to interpret regulations.
With the questions of what record the court will consider and how final the court's determination of subject matter jurisdiction will be at this point resolved, the court turns to consideration of the defendants' challenge to the plaintiffs' standing and the ripeness of their claims.
The defendants assert that the plaintiffs cannot make the required showing of injury in fact to establish their standing, because their constitutional claims fail as a matter of law. Moreover, the defendants contend that the plaintiffs cannot show any real or immediate threat that the FDA will institute an enforcement action against them, because they have not pointed to a single enforcement action by the government against others similarly situated, that is, individuals buying unpasteurized milk for personal consumption or retailers of unpasteurized milk purportedly not engaging in interstate commerce, nor do they allege that the FDA has in any way signaled an intention to enforce the challenged regulations against any of the
In response, the plaintiffs contend that they do not have to prove the merits of their claims to prove standing, they must only allege enough facts to raise a reasonable expectation that discovery will reveal evidence of illegal conduct. Moreover, they contend that, in the context of a declaratory judgment action, injury is not an element of standing. They contend that a declaratory judgment action gives them standing, because they have sufficient personal stake in the outcome of the controversy to assure adverse views are presented. They contend that the "Hobson's choice" that they face is sufficient to convey standing, because the Eighth Circuit Court of Appeals recognized in Minnesota Citizens Concerned for Life v. Federal Election Commission, 113 F.3d 129, 131 (8th Cir.1997), that a party has standing when he or she must either make significant changes to his or her conduct to obey a challenged law, or risk criminal or civil enforcement action by disobeying the regulation. The plaintiffs assert that the FDA has, in fact, taken the position that it is illegal for an individual to take raw milk across state lines and for dairy farmers to make raw milk available for distribution across state lines. Thus, they contend that they have alleged that they are engaged in allegedly illegal behavior and are refusing to modify their conduct to satisfy the FDA. They point specifically to the affidavit of Eric Wagoner concerning the incident in which he alleges that he was required by the FDA to dump raw milk that he had transported from South Carolina to Georgia. They assert that, if Wagoner was violating the regulations at issue, so too are all of the other individual plaintiffs when they legally obtain raw milk in neighboring states and transport it back to their home states. They contend that affidavits from counsel representing persons who are not parties here demonstrate that the FDA also considers it a violation of the regulations for a farmer, like plaintiff Buck, to make raw dairy products available in a state where it is legal to do so, if he knows that some of his customers take those raw dairy products across state lines.
In their Reply in further support of their motion, the defendants contend that nothing in the plaintiffs' resistance shows that they have standing to bring this action. Indeed, the defendants contend that the plaintiffs are unabashedly asking for an advisory opinion from this court, even though they have steadfastly refused to use the FDA's citizen's petition process to obtain an advisory opinion from the agency. They also contend that the Eighth Circuit Court of Appeals has rejected the notion that a declaratory judgment action
As the Eighth Circuit Court of Appeals has explained,
Gray, 567 F.3d at 983-84; see also True v. Nebraska, 612 F.3d 676, 679 (8th Cir.2010) (describing the requirements for standing as "(1) an injury in fact, (2) a causal connection between the injury and the conduct complained of, and (3) a likelihood that the injury is redressable by a favorable decision").
The gravamen of the "injury in fact" requirement for constitutional standing, at the motion to dismiss stage, is whether the plaintiffs have "asserted facts that affirmatively and plausibly suggest that they are indeed subject to a credible threat of prosecution under the [regulation] for engaging in conduct for which they invoke constitutional protection." Zanders v. Swanson, 573 F.3d 591, 594 (8th Cir.2009). "While general factual allegations of injury might suffice to establish standing in some instances, general allegations of possible or potential injury do not." Id. (emphasis in the original). The plaintiffs must "`nudge[ ] their claims across the line from conceivable to plausible.'" Id. (quoting Bell Atlantic Corp. v.
More specifically, plaintiffs have standing to challenge the facial validity of a regulation notwithstanding the pre-enforcement nature of a lawsuit, where the impact of the regulation is direct and immediate and they allege an actual, well-founded fear that the law will be enforced against them. Gray, 567 F.3d at 984. Thus, a plaintiff has standing to assert a facial challenge to the validity of a regulation or statute, even in the absences of a specific threat of enforcement, if the court need neither speculate nor attempt to anticipate whether that plaintiff will fall within the purview of the regulation, and the plaintiff alleges an intention to engage in a course of conduct that is clearly proscribed by statute. Id. In such circumstances, the presence of the regulation is threat enough. Id. at 986. The bar is not so high to show standing to assert a pre-enforcement as applied challenge to a regulation or statute, however. Although subjective apprehensions of enforcement are still not enough, see, e.g., Morrison v. Board of Educ. of Boyd County, 521 F.3d 602, 610 (6th Cir.2008), a plaintiff asserting a pre-enforcement as applied challenge need only demonstrate that a "credible threat of an injury exists," and may do so by showing (1) that the plaintiff was threatened with prosecution; (2) prosecution is likely; or (3) there is a credible threat of prosecution. See, e.g., American Charities for Reasonable Fundraising Regulation, Inc. v. Pinellas County, 221 F.3d 1211, 1214 (11th Cir.2000).
Injury is "fairly traceable" to the government conduct or regulation in question when there is an alleged causal connection between the government's conduct or regulation and the plaintiff's injury. Braden v. Wal-Mart Stores, Inc., 588 F.3d 585, 592 (8th Cir.2009). Moreover, "`[w]hen government action ... is challenged by a party who is a target or object of that action, ... "there is ordinarily little question that the action ... has caused him injury, and that a judgment preventing... the action will redress it."'" Monson v. Drug Enforcement Admin., 589 F.3d 952, 958 (8th Cir.2009) (quoting Minnesota Citizens Concerned for Life v. Federal Election Comm'n, 113 F.3d 129, 131 (8th Cir.1997), in turn quoting Lujan v. Defenders of Wildlife, 504 U.S. 555, 561-62, 112 S.Ct. 2130, 119 L.Ed.2d 351 (1992), with alterations by the Monson court).
More specifically, a provision of the FDCA, 21 U.S.C. § 321(b), defines "interstate commerce" to mean "(1) commerce between any State or Territory and any place outside thereof, and (2) commerce within the District of Columbia or within any other Territory not organized with a legislative body." Courts have interpreted the purpose behind the FDCA's interstate commerce regulation to be to "safeguard the consumer from the time the food is introduced into the channels of interstate commerce to the point that it is delivered to the ultimate consumer." United States v. Wiesenfeld Warehouse Co., 376 U.S. 86, 92, 84 S.Ct. 559, 11 L.Ed.2d 536 (1964); see also United States v. Sullivan, 332 U.S. 689, 696, 68 S.Ct. 331, 92 L.Ed. 297 (1948) (the provisions of the FDCA are "elements of an overall scheme designed to regulate the interstate flow of goods from the moment of their introduction into interstate commerce until the moment of their delivery to the ultimate consumer").
Moreover, courts have recognized that there are circumstances in which intrastate
The court also notes that, in the context of prohibitions on illegal drugs, the Eighth Circuit Court of Appeals has held that "[d]istribution under 21 U.S.C. § 841(a)(1) includes not only the sale of a controlled substance but also the non-commercial transfer from one person to another." United States v. Baswell, 792 F.2d 755, 760 n. 7 (8th Cir.1986). Thus, by analogy, "distribution" of raw dairy products under § 1240.61 can also plausibly be read to include transfer to another person, such as a family member, and such a distribution has occurred "after shipment in interstate commerce," where the raw dairy product was purchased out-of-state, and transported into the state by the purchaser to share with friends or family members.
The direct purchaser plaintiffs also contend that the FDA's direction that plaintiff Wagoner destroy the raw milk that he had purchased for himself, along with all of the other raw milk that he was transporting from South Carolina to Georgia for distribution to members of his virtual farmers' market, demonstrates that there is not only a credible threat that the FDA will enforce the regulations against a direct purchaser plaintiff, but that the FDA has actually done so. On the present record, the court must take as true the plaintiffs' allegations that Wagoner was told to destroy the raw milk that he was transporting across state lines for himself, because he had purchased it for himself, as well as the raw milk that he was transporting across state lines to distribute to others. The FDA has made no attempt to present evidence that it neither ordered Wagoner to destroy the raw milk, state officials did, nor ordered Wagoner to destroy the raw milk because he was attempting to transport some of the raw milk across state lines for his own consumption.
Thus, on the present record, the direct purchaser plaintiffs have made sufficient showing that they face a credible threat of injury to have standing.
Contrary to the defendants' contentions, these plaintiff's standing also is not defeated by a lack of causal connection between their alleged injury and the regulation or the unlikelihood that a favorable result will redress that injury. See Gray, 567 F.3d at 984 (further requirements for standing). When government action is challenged by a party who is a target or object of the government's action or regulation—as is the case here for direct purchaser plaintiffs, where their conduct is plausibly proscribed by the regulation— not only is there ordinarily little question that the government's action or regulation has caused that person injury, but little question that the judicial action will redress it. Monson, 589 F.3d at 958. The FDA's argument to the contrary misses the point. The fact that unpasteurized milk cannot be sold in the states where these plaintiffs live, so that even in the absence of the federal regulations, sales of raw milk would be unlawful in their states, is irrelevant: A declaration that the federal regulations in question are invalid would allow these plaintiffs lawfully to obtain raw milk from another state.
Thus, on the present record, taking the direct purchaser plaintiffs' allegations as true, they do have standing.
It is more than plausible, see Zanders, 573 F.3d at 594 (the plaintiffs must nudge their claim across the line from the conceivable to the plausible), it is likely and reasonable, to read the regulations in question as proscribing a principal (Cooper) from using an agent (Wagoner) to obtain raw milk out-of-state and to deliver it to the principal in the principal's home state, as Anne Cooper has allegedly done. Such conduct is plausibly proscribed by the prohibition on "caus[ing] [raw milk] to be delivered into interstate commerce," see 21 C.F.R. § 1240.61(a), where the principal and agent not only had a commercial relationship, but that relationship involves the interstate purchase and distribution of a good or commodity. Similarly, the conduct of the agent (Wagoner) is plausibly proscribed by the prohibition on "otherwise distribut[ing], or hold[ing] for sale or other distribution after shipment in interstate commerce any [raw milk]." See 21 C.F.R. § 1240.61(a). Wagoner alleges that he transports raw milk in interstate commerce, in that he transports the raw milk across state lines and delivers it to the members of his virtual farmers' market, pursuant to a commercial transaction.
These plaintiffs' standing also is not defeated by the defendants' contentions of a lack of causal connection between their alleged injury and the regulation or the unlikelihood that a favorable result will redress that injury. See Gray, 567 F.3d at 984 (further requirements for standing). When government action is challenged by a party who is a target or object of the government's action or regulation—as is the case here for plaintiffs Cooper and Wagoner, where their conduct is not only plausibly, but clearly proscribed by the regulation—not only is there ordinarily little question that the government's action or regulation has caused that person injury, but little question that the judicial action will redress it. Monson, 589 F.3d at 958. Again, the FDA's argument that, even in the absence of the federal regulations, sales of raw milk would be unlawful in their state, is irrelevant: A declaration that the federal regulations in question are invalid would allow these plaintiffs to obtain raw milk from another state.
Thus, the principal and agent plaintiffs do have standing.
Plaintiff Buck has made a preliminary showing that a "credible threat of an injury exists" from possible enforcement of the regulations against him. American Charities for Reasonable Fundraising Regulation, Inc., 221 F.3d at 1214. It is plausible to read the regulations in question to proscribe a producer, such as Buck, from selling raw milk in an intrastate transaction to purchasers from out of state. See Zanders, 573 F.3d at 594 (the plaintiffs must nudge their claim across the line from the conceivable to the plausible). Such a producer may plausibly be construed to have
Moreover, Buck has made an adequate preliminary showing that the FDA has enforced the regulation against other allegedly similarly-situated persons to show that there is a credible threat of prosecution against him.
Thus, Buck, the producer plaintiff, also has standing.
That part of the defendants' Motion To Dismiss seeking dismissal of the plaintiffs' claims for lack of standing will be denied.
The defendants contend that, even if the plaintiffs or some of them have standing, their claims are not ripe for judicial consideration. Because the court found above that the plaintiffs have made sufficient preliminary showing that they have standing, the court turns to consideration of the defendants' challenges to the ripeness of the plaintiffs' claims.
The defendants contend that the plaintiffs' claims are not fit for judicial consideration, because they do not raise purely legal issues. Rather, the defendants contend that the plaintiffs seek an advisory opinion from the court on mixed legal and factual issues, such as whether the many different actions purportedly taken by the plaintiffs to obtain raw milk from unidentified sources in numerous states would violate the FDA's regulations. The defendants contend that only in the context of specific enforcement action by the FDA will the agency have gathered the necessary evidence and made the requisite administrative determinations to permit meaningful judicial review. The defendants also argue that the plaintiffs posit a number of possible interpretations of the FDA's regulations that they contend could render their purported conduct unlawful, but that they do not show that the FDA has ever adopted such interpretations or
The plaintiffs agree that, in order for a declaratory judgment action to be "ripe," the issues should be largely legal in nature, those issues can be resolved without further factual development, and the resolution of the case will largely settle the parties' dispute. The plaintiffs contend that they satisfy these requirements, because they do face enforcement action from the FDA. They also argue that, because their allegations must be construed as true, the case presents purely legal issues of whether § 1240.61 and § 131.110 are unconstitutional as applied to them. Moreover, they contend that the issues should be addressed now to resolve this dispute so that the FDA and the plaintiffs can gain clarity on the application, scope, and extent of § 1240.61 and § 131.110.
In reply, the defendants assert that the plaintiffs are unabashedly seeking an advisory opinion, not adjudication of ripe claims, when they acknowledge that their claims are to "gain clarity" on the application, scope, and extent of the regulations.
As the Eighth Circuit Court of Appeals has explained,
Public Water Supply Dist. No. 10 of Cass County, Mo. v. City of Peculiar, Mo., 345 F.3d 570, 572-73 (8th Cir.2003). The court will consider each of these prongs of the ripeness analysis in turn.
The court is not persuaded by the defendants' contention that the plaintiffs are seeking an advisory opinion from the court on mixed legal and factual issues, such as whether many different kinds of actions would violate the FDA's regulations. The court also is not persuaded by the defendants' argument that only in the context of specific enforcement action by the FDA will the agency have gathered the necessary evidence and made the requisite administrative determinations to permit meaningful judicial review. Indeed, the court finds that the defendants are challenging the ripeness of the wrong claims: The plaintiffs' claims are not, as the defendants seem to assert, whether the many different actions purportedly taken by the plaintiffs to obtain raw milk from unidentified sources in numerous states would violate the FDA's regulations, but whether the regulations are unconstitutional or otherwise invalid.
Contrary to the defendants' contentions, this case poses the following essentially legal questions or, at least, questions not contingent on future possibilities, see Public Water Supply Dist. No. 10 of Cass County, Mo., 345 F.3d at 573:(1) whether the regulations in question violate the rights of persons who travel from one state, where it is not legal to purchase raw milk, to another state, where it is legal to purchase raw milk, legally purchase raw milk, then return to the original state where they consume the raw milk themselves or give it to their friends or family members; (2) whether the regulations in question violate the rights of a principal and agent who agree that the agent will obtain raw milk out-of-state, where it is legal to do so, and deliver it to the principal in the principal's home state, where sales of raw milk are not permitted; and (3) whether the regulations in question violate the rights of a producer of raw milk who sells raw milk in an intrastate transaction to persons that he knows are from out of state. The defendants have failed to identify any potentially important facts that are missing with respect to the purported application of the regulations to these plaintiffs, so that it is not incumbent on the court to decline to exercise jurisdiction over their claims. Yankton Sioux Tribe, 606 F.3d at 1015. Although "`[a] claim is not ripe for adjudication if it rests upon "contingent future events that may not occur as anticipated, or indeed may not occur at all,"'" Minnesota Pub. Utils. Comm'n, 483 F.3d at 582 (quoting Texas, 523 U.S. at 300, 118 S.Ct. 1257, in turn quoting Thomas, 473 U.S. at 580-581, 105 S.Ct. 3325), the court does not believe that principle requires that the plaintiffs be
The court concludes that the plaintiffs' claims are "fit" for judicial review.
Public Water Supply Dist. No. 10 of Cass County, Mo., 345 F.3d at 573.
The plaintiffs contend that denial of review would impose a hardship on them, because they are subject to imminent enforcement of the regulations in question against them. The defendants contend that they have not attempted to enforce the regulations against any of the plaintiffs, nor have they warned any of the plaintiffs of the possibility of enforcement action by warning letter, so that these plaintiffs cannot show that any injury is certainly impending. The defendants contend that even warning letters would not be enough to give the court subject matter jurisdiction over the plaintiffs' claims, because they do not commit the FDA to enforcement action, citing Biotics Research Corp. v. Heckler, 710 F.2d 1375, 1378 (9th Cir.1983), and Clinical Reference Lab., Inc. v. Sullivan, 791 F.Supp. 1499, 1504 (D.Kan.1992).
The defendants contend that plaintiff Wagoner's allegations of actual enforcement action against him and against one of his principals, Cooper, are "bizarre" and unsupported. The defendants contend that, if the FDA, rather than state officials, had actually ordered the destruction of the raw milk as alleged, the FDA would have done so in a in rem seizure action, pursuant to the Food, Drug, and Cosmetic Act (FDCA), 21 U.S.C. § 334, in which Wagoner (and presumably Cooper) would have had the opportunity to appear and object, but there is no evidence of any such action. Interestingly, the defendants do not dispute Wagoner's contention that a FDA agent was present at the destruction of the raw milk, nor do they offer any evidence demonstrating that the destruction of the raw milk was entirely on the authority of Georgia state officials, not the FDA. Under the circumstances, where the court has construed the defendants' challenge to subject matter jurisdiction as essentially facial, the court must take as true the plaintiffs' allegations that the FDA ordered the destruction of the raw milk that Wagoner was transporting across
As to the "hardship" of the other plaintiffs, the court does not find that the lack of warning letters means that these plaintiffs' claims are not "ripe." The court acknowledges that, in Biotics Research Corporation and Clinical Reference Laboratory, other courts concluded that warning letters sent to the plaintiffs, warning of possible agency enforcement action, were not enough to make the plaintiffs' claims ripe, because the warning letters did not constitute final agency action that would have established sufficiently imminent injury. See Biotics Research Corp., 710 F.2d at 1376 & 1378; Clinical Reference Lab., Inc., 791 F.Supp. at 1503-04. Here, none of the plaintiffs have alleged that they have even received warning letters. The court disagrees with the decisions in Biotics Research and Clinical Reference Laboratory to the extent that they could be read to require final agency action, or notice from an agency committing the agency to enforcement action, to establish sufficiently imminent injury to show "hardship" and, consequently, "ripeness." Such a rule would mean that no pre-enforcement challenge to agency regulations is ever ripe, but the test is whether the plaintiffs have alleged that they have sustained or are immediately in danger of sustaining some direct injury as the result of the challenged statute or official conduct. See Public Water Supply Dist. No. 10 of Cass County, Mo., 345 F.3d at 573. The "hardship" prong of the "ripeness" analysis does not require the plaintiff to wait until the threatened injury occurs. Id.
For much the same reason that the court found that the direct purchaser plaintiffs had made sufficient preliminary showing of a credible threat of injury, for standing purposes, the court now finds that they have made sufficient preliminary showing that they are in immediate danger of sustaining some direct injury, as the result of the challenged regulations, for ripeness purposes. These plaintiffs have made an essentially unchallenged showing that Wagoner, a similarly-situated plaintiff, was ordered to destroy milk that he had purchased for himself then transported across state lines and that such conduct plausibly falls within the prohibitions of the regulations. Furthermore, for much the same reason that the court found that the producer plaintiff, plaintiff Buck, had made sufficient preliminary showing of a credible threat of injury, for standing purposes, the court now finds that he has made sufficient preliminary showing that he is in immediate danger of sustaining some direct injury, as the result of the challenged regulations, for ripeness purposes. Plaintiff Buck has made an essentially unchallenged showing that a similarly-situated producer was subject to a FDA criminal enforcement action, because, like him, that producer knew that some buyers of his raw milk were from out of state and that they were taking the raw milk back to their own states for human consumption. See Amended Complaint, ¶ 42.
Therefore, the plaintiffs also satisfy the "hardship" prong of the "ripeness" analysis.
That part of the defendants' Motion To Dismiss seeking dismissal of the claims of the plaintiffs on "ripeness" grounds will be denied.
The last arrow in the defendants' quiver as they attempt to shoot down the plaintiffs' claims for lack of subject matter jurisdiction is that the plaintiffs' claims for declaratory and injunctive relief barring the government from applying the FDA's regulations are foreclosed by Ewing v. Mytinger & Casselberry, Inc., 339 U.S. 594, 70 S.Ct. 870, 94 L.Ed. 1088 (1950). The plaintiffs dispute the applicability of Ewing to their claims.
The defendants assert that Ewing bars actions for judicial review at preliminary phases of the FDA's administrative procedures, such as whether or not to institute enforcement actions at all. The defendants argue that, if the FDA were to determine that the plaintiffs' alleged conduct violates FDA regulations prohibiting the interstate sale and distribution of unpasteurized milk, then the government would have the discretion to initiate a seizure or injunctive action pursuant to provisions of the FDCA, 21 U.S.C. §§ 332 and 334. At that time, the defendants argue, the plaintiffs would have the opportunity to raise and litigate the claims that they advance in the present action. At this time, however, the defendants contend, the plaintiffs' request is for this Court to enjoin all such future enforcement action, but that request is plainly foreclosed by Ewing and its progeny.
The plaintiffs contend that Ewing is simply not on point, because the Supreme Court has determined that Ewing does not apply to a declaratory judgment action, even a pre-enforcement action, in Abbott Laboratories v. Gardner, 387 U.S. 136, 87 S.Ct. 1507, 18 L.Ed.2d 681 (1967). Although they acknowledge that Abbott has been overturned as to its holding that the Administrative Procedures Act (APA) grants federal courts an independent jurisdictional basis to hear challenges to agency action, they contend that Abbott is still controlling on the ability of litigants to bring declaratory judgment actions to challenge the application of final agency action.
In reply, the defendants argue that Ewing forecloses the plaintiffs' action, because the plaintiffs expressly prayed for injunctive relief enjoining further enforcement of the regulations against them. In a rather dramatic reformulation of their argument, however, the defendants also contend that the plaintiffs do not meet the Abbott ripeness standard, because the parties here do not agree that the issues presented are purely legal or that the regulations are directed at the plaintiffs in particular, and the FDA has not indicated that immediate compliance with its regulations is expected. Indeed, the FDA argues that it is by no means clear that the regulations in question even touch the plaintiffs' alleged conduct. The defendants contend that this case is more akin to Toilet Goods Association v. Gardner, 387 U.S. 158, 87 S.Ct. 1520, 18 L.Ed.2d 697 (1967), in which the Supreme Court held that the judicial review was not appropriate where the court had no idea whether or when the challenged FDA regulation would be enforced or what reasons the Commissioner would give to justify the enforcement order. The defendants contend that the Court reached that conclusion in Toilet Goods, even though there was no question that the FDA's regulation constituted final agency action and the challenge to it was a purely legal question. The defendants argue that, just as in Toilet Goods, the present dispute requires additional factual development—whether through plaintiffs' submission of a citizen petition or a FDA investigation and enforcement action—before this court could have sufficient information to determine whether the challenged regulations even apply to the plaintiffs' conduct.
The court finds the defendants' reliance on Ewing to be particularly ill-founded. This is so, even though the defendants are correct that the plaintiffs pray, inter alia, for "[a]n injunction enjoining any further enforcement, civil, criminal, administrative or otherwise, of [the regulations] against Plaintiffs." Amended Complaint at 26, ¶ G. Although Ewing bars judicial review of and injunctive relief against preliminary phases of administrative procedures to enforce regulations, including the determination of whether or not to institute an enforcement action, see Ewing, 339 U.S. at 600-01, 70 S.Ct. 870, nothing in Ewing bars a court from hearing an action for declaratory judgment concerning the validity of final agency regulations in which there is an incidental, perhaps overbroad, prayer for injunctive relief pursuant to the declarations sought. The bar in Ewing on enjoining preliminary phases of administrative procedures to enforce regulations simply has no application, where there are no administrative procedures to enforce the regulations at issue currently afoot. The defendants' reading of Ewing would preclude any and all pre-enforcement declaratory challenges to regulations if there is a prayer for incidental injunctive relief. Ewing does not reach so far.
Moreover, contrary to the defendants' belated retrenchment, this case is closer to Abbott than to Toilet Goods. Contrary to the defendants' contentions, the court concluded above that the challenge by the plaintiffs poses the following legal questions, or at least questions not contingent on future possibilities: (1) whether the regulations in question violate the rights of persons who travel from one state, where it is not legal to purchase raw milk, to another state, where it is legal to purchase raw milk, legally purchase raw milk, then return to the original state where they consume the raw milk themselves or give it to their friends or family members; (2) whether the regulations in question violate the rights of a principal and agent who agree that the agent will obtain raw milk out-of-state, where it is legal to do so, and to deliver it to the principal in the principal's home state, where sales of raw milk are not permitted; and (3) whether the regulations in question violate the rights of a producer of raw milk who sells raw milk in an intrastate transaction to persons that he knows are from out of state. The defendants have failed to identify any potentially important facts that must be determined through a citizen petition or agency enforcement action that are necessary to determine the applicability of the regulations to the conduct of these plaintiffs, where the court held, above, that the plaintiffs have made an adequate preliminary showing that the regulations plausibly proscribe their conduct and that the FDA stands ready to enforce the regulations against conduct such as theirs.
Thus, the questions presented here are purely legal and based on undisputed factual circumstances, and it appears that the FDA does stand ready to enforce compliance with the regulations, to the extent that the FDA has purportedly already enforced them against these plaintiffs and allegedly similarly situated persons. Compare Abbott, 387 U.S. at 146-47, 87 S.Ct. 1507 (finding that an action for judicial review was not foreclosed by Ewing where the FDA had already formally promulgated the regulation in question, the regulation was "self-operative," and foreclosure of an action in such circumstances would immunize nearly all agency rule-making from review under the APA, and while Ewing barred interference with the early stages of administrative determinations as to specific facts, it did not bar well-established jurisdiction of the federal courts to hear suits under the Declaratory Judgment
The defendants' final attack on the court's subject matter jurisdiction over the plaintiffs' claims, thus, fails, at least on the present record.
The court concludes—in light of the present submissions and the failure of the defendants to mount an unambiguously factual challenge to subject matter jurisdiction—that the plaintiffs have standing to pursue their claims and that those claims are ripe for judicial determination. The court reiterates, however, that these conclusions are preliminary, and turn in large part on the court's obligation to take as true the plaintiffs' jurisdictional allegations, in the absence of a full-fledged factual challenge to subject matter jurisdiction and a request for an evidentiary hearing by the defendants.
The defendants also mount several challenges pursuant to Rule 12(b)(6) to the plaintiffs' Amended Complaint on the ground that the Amended Complaint fails to state claims upon which relief can be granted. However, the court finds that only one of those challenges, the plaintiffs' alleged failure to exhaust administrative remedies, must be addressed at this time, in light of the court's strictly preliminary determination that the plaintiffs have standing and that their claims are ripe. Although failure to exhaust administrative remedies is not a jurisdictional impediment, see Teva Pharm. USA, Inc. v. Sebelius, 638 F.Supp.2d 42, 51 (D.D.C.2009), rev'd on other grounds, 595 F.3d 1303 (D.C.Cir.2010), the defendants' failure-to-exhaust challenge is, nevertheless, another version of the defendants' overarching contention that the plaintiffs' claims are not yet ready for judicial determination.
The defendants contend that dismissal is appropriate, where the plaintiffs have failed to avail themselves of the administrative process. They contend that the plaintiffs have made no attempt to avail themselves of, much less exhaust, administrative remedies available to them, consisting of a citizen's petition with the FDA pursuant to 21 C.F.R. §§ 10.25 and 10.30. The defendants contend that, pursuant to 21 C.F.R. § 10.45(b), before any legal action is filed in a court, a party must first file a citizen petition to request that the Commissioner take or refrain from taking any form of administrative action and, pursuant to 21 C.F.R. § 10.45(d), the FDA's response to such a petition constitutes reviewable final agency action. Here, the defendants argue that the plaintiffs' attempt to bypass the administrative process means that they have precluded meaningful and efficient judicial review, which would have allowed the FDA to consider and address the plaintiffs' concerns and which could have resolved or at least crystalized the issues.
The plaintiffs counter that exhaustion of administrative remedies does not apply to a declaratory judgment action such as this. The plaintiffs contend that there are no administrative remedies for them to exhaust, because the requirement for administrative proceedings, on its face, does not apply to an as-applied challenge to the constitutionality of the regulations through a declaratory judgment action. The plaintiffs also contend that promulgation of the regulations is reviewable final agency action. The plaintiffs next contend that the FDA lacks authority to rule on the constitutionality
Rule 12(b)(6) provides for a motion to dismiss for failure to state a claim upon which relief can be granted. The defendants assert that failure to exhaust administrative remedies under FDA regulations warrants dismissal pursuant to Rule 12(b)(6), citing Association of Am. Physicians & Surgs., Inc. v. FDA, 539 F.Supp.2d 4, 22 (D.D.C.2008). This court will assume, without deciding, that failure to exhaust the FDA's administrative remedies warrants dismissal for failure to state a claim pursuant to Rule 12(b)(6), where exhaustion of administrative remedies is required by statute or regulation.
As the defendants point out, "[t]he basic purpose of the exhaustion doctrine is to allow an administrative agency to perform functions within its special competence—to make a factual record, to apply its expertise, and to correct its own errors so as to moot judicial controversies." See Parisi v. Davidson, 405 U.S. 34, 37, 92 S.Ct. 815, 31 L.Ed.2d 17 (1972). If interested parties were allowed to bypass administrative remedies, the entire regulatory process would be undermined, and "[c]ourts would constantly have to address new arguments that were never presented to the agency." Association of Am. Physicians & Surgeons, Inc., 539 F.Supp.2d at 22. Moreover, "[a]n administrative agency, which is not subject to Article III of the Constitution of the United States and related prudential limitations, may issue a declaratory order in mere anticipation of a controversy or simply to resolve an uncertainty." Pfizer, Inc. v. Shalala, 182 F.3d 975, 980 (D.C.Cir. 1999) (citing Metropolitan Council of NAACP Branches v. FCC, 46 F.3d 1154, 1161 (D.C.Cir.1995)).
However, as the plaintiffs point out, a party "cannot `properly be required to exhaust a remedy which may not exist.'" Parisi, 405 U.S. at 44, 92 S.Ct. 815 (quoting Noyd v. Bond, 395 U.S. 683, 698 n. 11, 89 S.Ct. 1876, 23 L.Ed.2d 631 (1969)). Moreover,
Teva Pharm., 638 F.Supp.2d at 51; see also Chorosevic v. MetLife Choices, 600 F.3d 934, 945 (8th Cir.2010) (also recognizing,
These principles bring the court to the question of whether and for what questions administrative exhaustion is required by FDA regulations. As a colleague in a sister district has concisely explained, "FDA regulations require that, before filing suit in court, a party requesting that the FDA take or refrain from taking an action must first use the citizen petition process set forth in 21 C.F.R. § 10.25." Teva Pharm., 638 F.Supp.2d at 51 (citing 21 C.F.R. § 10.45(b)). The FDA's response to a citizen petition is deemed to be a "`final agency action ... reviewable in the courts.'" Pfizer, 182 F.3d at 979-80 (quoting 21 C.F.R. § 10.45(d)); Schering Corp. v. FDA, 51 F.3d 390, 393 (3d Cir.1995).
Somewhat more specifically, 21 C.F.R. § 10.25(a) provides that "[a]n interested person may petition the Commissioner [1] to issue, amend, or revoke a regulation or order, or [2] to take or refrain from taking any other form of administrative action." (Emphasis added). That regulation provides, further, that "a petition must be either ... [i]n the form specified [for specific agency actions], or ... in the form of a citizen petition in § 10.30." 21 C.F.R. § 10.25(a). Section 10.45(b) makes certain administrative exhaustion mandatory:
21 C.F.R. § 10.45(b) (emphasis added). Although this exhaustion requirement expressly applies to requests that the Commissioner "take or refrain from taking any form of administrative action," one category of requests that may be asserted in an administrative petition pursuant to § 10.25(a), conspicuous by its absence is any reference to the other category of requests identified in § 10.25(a), requests that the Commissioner "issue, amend, or revoke a regulation or order." See 21 C.F.R. § 10.25(b).
Even so, this court is not convinced that the plaintiffs' claims fall into either of the categories of claims for which a citizen petition is appropriate or required pursuant to 21 C.F.R. § 10.25(b). If this action were for review of a specific administrative enforcement action, then it clearly would fall within the scope of the
The part of the defendants' Motion To Dismiss seeking dismissal of the plaintiffs' claims for failure to exhaust administrative remedies will be denied.
On the other hand, there are questions ante to the plaintiffs' constitutional claims that would fall within the scope of a citizen petition pursuant to § 10.25, if presented as a request that the FDA take administrative action to interpret the authorizing statutes and regulations. Such a request for agency action also falls squarely within the administrative agency's expertise.
More specifically, one of the fundamental disputes in this is that the plaintiffs assume, albeit supported by some circumstantial evidence, that the FDA believes that the plaintiffs' conduct falls within the proscriptions of § 1240.61, while the defendants' assert that the FDA has not and does not intend to enforce the regulations against any of the plaintiffs or persons similarly situated to the plaintiffs. In the context of this dispute, the precise question appropriate for administrative determination, in the first instance, is whether § 1240.61 applies to and proscribes the conduct of (1) persons who travel from one state, where it is not legal to purchase raw milk, to another state, where it is legal to purchase raw milk, legally purchase raw milk, then return to the original state where they consume the raw milk themselves or give it to their friends or family members; or (2) a principal and agent who agree that the agent will obtain raw milk out-of-state, where it is legal to do so, and to deliver it to the principal in the principal's home state, where sales of raw milk are not permitted; or (3) a producer of raw milk who sells raw milk in an intrastate transaction to persons that he knows are from out of state. This question presents constituent questions of the scope of the authorizing statutes and the regulations at issue, including whether the plaintiffs' conduct involves or affects "interstate commerce" sufficiently to fall within the proscriptions of § 1240.61, and, still more specifically, whether the plaintiffs' conduct constitutes "delivery [of raw dairy products] into interstate commerce" or "distribution" of raw dairy products after shipment in interstate commerce.
The court is not convinced by the plaintiffs' assertions that any administrative proceedings would be futile. See, e.g., Teva Pharm., 638 F.Supp.2d at 51 (a claimant need not exhaust futile administrative remedies). The allegedly entrenched position attributed to the FDA by the plaintiffs—that raw milk should not be consumed by anyone—simply does not directly implicate any of the questions posed just above. Nor does the FDA's alleged inaction on a citizen petition by a non-party, asking the FDA to amend or rescind § 1240.61 and/or § 131.110 to allow the interstate shipment of raw dairy products between two different states in the United States that both allow the legal sale of raw dairy products, see Plaintiffs' Resistance, Exhibit D, demonstrate that a citizen petition posing different questions—the questions ante identified above—is necessarily futile. Indeed, the court finds the plaintiffs' contentions that administrative proceedings on any question would be futile to be, at best, speculative and, hence, insufficient to excuse exhaustion of the questions ante identified just above. Chorosevic, 600 F.3d at 945 ("`Unsupported and speculative claims of futility do not excuse a claimant's failure to exhaust his or her administrative remedies,'" quoting Midgett, 561 F.3d at 898).
Consequently, the court finds that the prudent course is to stay proceedings to allow the plaintiffs to determine whether or not to pursue a citizen petition presenting to the agency the questions ante posed above, then revisit, if necessary, the questions of standing, ripeness, and failure to state claims upon which relief can be granted.
Faced with the uncertain nature of the defendants' challenge to the court's subject matter jurisdiction, the court has construed the challenge as essentially a preliminary, facial one. The court finds, however, that the plaintiffs have made sufficient preliminary showing of standing and ripeness to deny the defendants' Motion To Dismiss for lack of subject matter jurisdiction, without prejudice to reassertion of a full factual challenge. Although the court does not find that administrative exhaustion is required for the plaintiffs' present claims, the court does find that it would be prudent to allow the plaintiffs time to pursue a citizen petition pursuant to 21 C.F.R. § 10.25 raising certain questions ante, identified above.
THEREFORE,
1. That part of the defendants' April 26, 2010, Motion To Dismiss (docket no. 10) asserting lack of subject matter jurisdiction is
2. That part of the defendants' April 26, 2010, Motion To Dismiss (docket no. 10) asserting failure to state a claim upon which relief can be granted is
3. Proceedings in this court are
4. The plaintiffs' July 24, 2010, Motion To Admit Newly Discovered Evidence (docket no. 24) is